RemedyMD’s solution addresses Institute of Medicine’s top 100 priorities and shifts focus towards research based on more comprehensive scientific evidence

Salt Lake City, UT -- (SBWire) -- 11/16/2009 -- RemedyMD, the leading provider of disease registry software, today announced the first nationwide renal replacement therapies registry. The new registry was developed to help clinicians and researchers identify which interventions are most appropriate for specific patient populations.

Details about the registry: http://www.remedymd.com/cer100/renal_therapies.html

Aligned with the Institute of Medicine’s Top 100 Priorities for Comparative Effectiveness Research (CER), RemedyMD’s renal therapies registry compares the effectiveness (including survival, hospitalization, quality of life, and costs) of renal replacement therapies including:

* Daily home hemodialysis
* Intermittent home hemodialysis
* Conventional in-center dialysis
* Continuous ambulatory peritoneal dialysis
* Renal transplantation

for patients of different ages, races, and ethnicities. The registry includes all of the applications, data infrastructure, and tools that clinicians and researchers need to gather, synthesize and analyze both phenotypic and genotypic data simultaneously.

“Our experience has shown when you view and report across all data types at the same time, you discover patterns and associations that are indistinguishable using traditional methodologies” said Gary D. Kennedy, Founder and CEO of RemedyMD.

RemedyMD’s new renal therapies registry includes a comprehensive set of electronic data collection (EDC) forms that are specific to kidney research, ad hoc reporting capability, and pattern recognition tools that assist users in identifying the most effective treatment options.

In support of this initiative RemedyMD is seeking additional partners who have existing data that addresses the specific needs of kidney researchers. All institutions involved in comparative effectiveness research that are planning on submitting grant proposals for AHRQ funding are invited to visit: http://www.remedymd.com/cer100/renal_therapies.html

RemedyMD Resources:
Resource Kit for Comparative Effectiveness Research: http://www.remedymd.com/cer_kit

Ways to leverage Renal Therapies Registry: http://www.remedymd.com/cer100/renal therapies

Comparative Effectiveness Research: http://www.remedymd.com/cer_home

Disease Registry Software: http://www.remedymd.com/registries_home

Institute of Medicine’s Top 100 Priorities for CER: http://www.remedymd.com/cer_kit

About RemedyMD
RemedyMD® is the leading provider of specialized software applications, tools, and data necessary for comparative effectiveness research with more than 100 pre-built clinical, disease, and patient registry software applications. RemedyMD solutions are personalized to the institution, the clinical specialty, and to the individual provider’s preferences enabling researchers to identify new patterns, facilitate new discoveries, and improve medical outcomes. For more information, visit http://www.RemedyMD.com.

Press Contact:
Lane Peterson
RemedyMD
SALT LAKE CITY, US
801.733.3383
lpeterson@remedymd.com
http://www.RemedyMD.com